Hence, irisin has been proposed as an appealing therapeutic target in cases of muscle atrophy and metabolic diseases, such as obesity, diabetes, and non-alcoholic fatty liver disease (Polyzos et al., 2018). The gene discussed is FNDC5; the disease is Other metabolic disease.